Rockefeller Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.5K Hold
19,231
– – ﹤0.01% 3921
2026
Q2
$22.1K Hold
19,231
– – ﹤0.01% 3704
2026
Q1
$14.6K Hold
19,231
– – ﹤0.01% 3839
2025
Q4
$26K Hold
19,231
– – ﹤0.01% 3387
2025
Q3
$26K Buy
+19,231
New +$26.2K ﹤0.01% 3219

Other funds holding CGTX

Rockefeller Capital Management's CGTX Position: Q3 2026 in Review

Rockefeller Capital Management held its Cognition Therapeutics (CGTX) position steady in Q3 2026 at 19,231 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

Rockefeller Capital Management first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $26K in Q4 2025. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • Rockefeller Capital Management held 19,231 shares of Cognition Therapeutics worth $18.5K as of Q3 2026.
  • Rockefeller Capital Management left its Cognition Therapeutics share count unchanged in Q3 2026.
  • Cognition Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3921 holding.
  • Rockefeller Capital Management first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Cognition Therapeutics position peaked at $26K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.